Product Overview
Dragon Pharma Testagen leaves the shelf as one 20 mg vial of freeze-dried powder. The active content is KEDG, a four-residue regulatory peptide made from lysine, glutamic acid, aspartic acid and glycine, and it sits in the same short bioregulator series that the research literature credits with influencing transcription in cell models. It is not a gonadotropin, not an androgen and not a hormone of any kind, which matters because the way the vial is marketed leans heavily on a male reproductive story.
That marketing angle deserves a plain statement. Supplier pages describe testicular tissue and male reproductive support, and the wording is similar from shop to shop, but similarity between vendors is not evidence. The peptide does not replace testosterone replacement therapy and there is no confirmed report of it moving testosterone levels in people. Buyers who want a compound with actual human gonadotropin data are looking at a different class of product altogether, and the honest comparison is made later on this page.
Before any of that, the vial has to be turned into a solution. Bacteriostatic water is the standard solvent for this format, and the concentration you obtain is decided by the volume you introduce rather than by the label weight. The family relatives studied in the same research writing include Epitalon and the metabolic cofactor NAD+, and both appear again below as companion purchases.
Reconstitution and Reference Amounts
Nothing here is a clinical schedule. The figures are solvent arithmetic and quoted vendor ranges for a compound with no human trial data, and the same vial behaves very differently depending on how much water goes in.
| Solvent | Bacteriostatic water added slowly against the wall of the vial; the powder is not shaken |
| 20 mg in 2 ml | 10 mg/ml. One milligram measures 0.1 ml, or 10 units on a U-100 insulin syringe; two milligrams measures 0.2 ml, or 20 units |
| 20 mg in 1 ml | 20 mg/ml. One milligram measures 0.05 ml, small enough to need a low-volume or low-dead-space syringe |
| Quoted vendor range | Supplier pages mention 0.5-2 mg a day by the subcutaneous route; no controlled study backs any figure |
| Vial duration | 20 mg gives about 20 days at 1 mg a day, or about 10 days at 2 mg a day |
| Course format in the project base | Short blocks of 1-3 weeks, repeated once or twice a year, with breaks in between |
| Stability | Refrigerate the dry powder between 2 and 8 C, keep it dark and never freeze it; a mixed vial lasts about four weeks |
| Female | The sources behind this card contain no verified female schedule, and none is proposed here |
Research Protocols
The peptide is grouped in research writing in a few ways. None of these arrangements was tested as a combination, and the durations reflect the family habit of short blocks rather than any proven course length.
Testagen belongs to a family rather than to a class, and the family is handled one position at a time. Epitalon, Livagen, Ovagen and Testagen are separate short peptides from the same bioregulator series, each in its own vial and each identified by its own letter code - KEDG here, KEDA in Livagen, EDL in Ovagen - and none of them is blended with another in this line. A research plan that uses two of them runs one position and then the next rather than drawing both into one syringe, because no combined vial is sold and no study has looked at a mixture. NAD+, stocked beside them, is not a peptide at all but a cofactor, and it sits at a different level of the same metabolic story.
What to Expect
- Opening days. A local reaction around the injection point is the only event the first 1-3 days reliably produce; do not wait for a systemic surge.
- First fortnight. Online accounts discuss a general sense of tone, and without clinical measurement those accounts cannot be told apart from expectation.
- Weeks 2-3. This closes the family-style short block; the sources offer no reason to run it longer.
- Reproductive framing. The testicular and fertility narrative is a vendor position, not a measured endpoint.
- Hormone expectations. No separate effect on human testosterone levels is recorded in the sources, and this is marked as unconfirmed rather than as a benefit.
- Family mechanism. The series is studied at the level of histone interaction and promoter access in cultures, which is the origin of the broader claims.
- Evidence ceiling. There are no human trials and no approval anywhere, so the product is a research material by definition.
Side Effects and Management
There are no frequency figures for this peptide, so the list below is drawn from class-level behaviour of short injected peptides and from the errors that surround them. It is not a measured safety profile.
Monitoring, Storage and No PCT
Testagen does not suppress the gonadal axis, so no restart protocol is required after a block. The useful work is baseline bloodwork, careful storage and a second panel at the end.
Solvent is a purchase in its own right here, so Bacteriostatic water belongs on the same order. Where the target is genuine gonadal stimulation rather than a research peptide, HCG 2500 iu is the agent with human data, and a restart protocol after suppression is built from Clomid or Nolvadex rather than from any bioregulator. Estrogen control, if bloodwork ever calls for it, runs on a low dose of Arimidex and never on a fixed schedule.
Planning a block is arithmetic before it is anything else. A 20 mg vial delivers about twenty days at the vendor reference of 1 mg a day and about ten days at 2 mg a day, so a three week block at the lower figure needs more than one vial and a two week block at the upper figure does not. Because the powder and the mixed solution are both stored cold, the order, the solvent and the block length belong in the same calculation rather than being decided one at a time.
